Franklin Street Advisors Lifted Idexx Laboratories (IDXX) Position By $3.07 Million; REZOLUTE (RZLT) Shorts Increased By 3%

February 24, 2018 - By Dolores Ford

REZOLUTE INC (OTCMKTS:RZLT) had an increase of 3% in short interest. RZLT’s SI was 10,300 shares in February as released by FINRA. Its up 3% from 10,000 shares previously. With 10,000 avg volume, 1 days are for REZOLUTE INC (OTCMKTS:RZLT)’s short sellers to cover RZLT’s short positions. The SI to REZOLUTE INC’s float is 0.06%. The stock 0.02% or $0 during the last trading session, reaching $0.62. It is down 0.00% since February 24, 2017 and is . It has underperformed by 16.70% the S&P500.

Franklin Street Advisors Inc increased Idexx Laboratories (IDXX) stake by 85.26% reported in 2017Q3 SEC filing. Franklin Street Advisors Inc acquired 19,785 shares as Idexx Laboratories (IDXX)’s stock rose 13.64%. The Franklin Street Advisors Inc holds 42,990 shares with $6.69M value, up from 23,205 last quarter. Idexx Laboratories now has $16.35B valuation. The stock increased 2.04% or $3.75 during the last trading session, reaching $187.61. About 461,498 shares traded. IDEXX Laboratories, Inc. (NASDAQ:IDXX) has risen 83.30% since February 24, 2017 and is uptrending. It has outperformed by 66.60% the S&P500.

Rezolute, Inc., a clinical stage biopharmaceutical company, specializes in the development of drug therapies for treating diabetes and metabolic diseases in the United States. The company has market cap of $33.53 million. The Company’s lead product candidate is AB101, which is a human recombinant insulin that is used alone and in combination with bolus prandial insulin or oral glucose lowering therapies to enhance glycemic control in patients with type 1 and type 2 diabetes mellitus has completed phase I clinical trial. It currently has negative earnings. The firm also develops AB301, a human glucagon-like peptide-1 agonist for the treatment of patients with type 2 diabetes; AB402 for vision-threatening eye complications of diabetes, including Diabetic Retinopathy and Diabetic Macular Edema; and AB602 to treat Hereditary Angioedema, which are in preclinical studies.

Investors sentiment decreased to 0.86 in Q3 2017. Its down 0.33, from 1.19 in 2017Q2. It dived, as 39 investors sold IDXX shares while 196 reduced holdings. 55 funds opened positions while 146 raised stakes. 87.85 million shares or 15.07% more from 76.34 million shares in 2017Q2 were reported. Goldman Sachs Grp owns 621,160 shares. Guardian Life Insurance Company Of America reported 198 shares. Highland Capital Lc accumulated 1,710 shares. Korea Invest holds 0.06% of its portfolio in IDEXX Laboratories, Inc. (NASDAQ:IDXX) for 82,332 shares. Cahill Fincl Advsrs reported 1,300 shares. 2,650 were accumulated by Moneta Group Incorporated Investment Lc. Bancorp Of Montreal Can has 353,001 shares. Ohio-based Huntington Retail Bank has invested 0% in IDEXX Laboratories, Inc. (NASDAQ:IDXX). Conestoga Capital Advsrs Ltd Liability Co holds 0.08% or 11,351 shares. United Kingdom-based Marshall Wace Limited Liability Partnership has invested 0.08% in IDEXX Laboratories, Inc. (NASDAQ:IDXX). Stratos Wealth has 0.01% invested in IDEXX Laboratories, Inc. (NASDAQ:IDXX) for 1,464 shares. Martingale Asset Ltd Partnership, Massachusetts-based fund reported 2,902 shares. First Personal Fincl Ser reported 0.02% stake. State Treasurer State Of Michigan reported 26,500 shares. Hillhouse Mgmt Ltd holds 0.11% of its portfolio in IDEXX Laboratories, Inc. (NASDAQ:IDXX) for 41,725 shares.

Since August 28, 2017, it had 2 insider purchases, and 4 insider sales for $20.16 million activity. 1,000 shares were bought by Claflin Bruce L., worth $179,580 on Wednesday, February 7. Another trade for 13,000 shares valued at $1.96M was made by AYERS JONATHAN W on Monday, August 28. $1.20M worth of IDEXX Laboratories, Inc. (NASDAQ:IDXX) was sold by MCKEON BRIAN P. The insider Kingsley Lawrence D bought 1,000 shares worth $178,045.

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: